RESEARCH PUBLICATIONS

CRI regularly issues presentations, abstracts, and medical journal articles based on its research findings, often in collaboration with other HIV and infectious disease experts.

Click below for more information on presentations, abstracts, and medical journal articles published by CRI researchers.

If you have questions about CRI’s research publications, please contact the CRI Communications team at 617.502.1726.

MEDICAL JOURNAL ARTICLES


Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner JW, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM., Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchinson JG, Stedman CAM, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, & Sulkowski M. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1The New England Journal of Medicine. July 21, 2015. doi:10.1056/NEJMoa1501315

 

Nelson MR, Elion RA, Cohen CJ, et al. Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies. HIV Clinical Trials. 14(3):81–91 May-Jun 2013. Thomas Land Publishers. doi:10.1310/hct1403-81

 

 

Zolopa A, Sax P, DeJesus E, Mills A, Cohen CJ, Wohl D, et al. A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. JAIDS. May 2013.

 

 

Sax PE, Cohen CJ, Kuritzkes DR, eds. HIV Essentials. Burlington, VT: Jones & Bartlett, 2013.

 

 

 

Sax P, DeJesus E, Mills A, Zolopa A, Cohen CJ, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. The Lancet. June 2012; 379(3): 2439-2448.

 

 

 

RESEARCH PRESENTATIONS + ABSTRACTS

Cohen C, Wohl D, Cavassini M, et al. STaR study: Single-tablet regimen rilpivirine/emtricitabine/tenofovir DF is non-inferior compared to
efavirenz/emtricitabine/tenofovir DF and improves patient reported outcomes through week 96.
Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-September 9, 2014; Washington, DC.

 

Shalit P, Cohen CJ, Mills A, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF demonstrates comparable efficacy to efavirenz/emtricitabine/tenofovir DF in subjects with adherence <95%. Presented at: 7th International IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013; Kuala Lumpur, Malaysia.

 

Cohen CJ. STaR study: single tablet regimen rilpivirine/emtricitabine/tenofovir DF has non-inferior efficacy compared to efavirenz/emtricitabine/tenofovir DF and improves patient reported outcomes. Presented at: 7th International IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013; Kuala Lumpur, Malaysia.

 

Cohen C, Green J, Olivet H, Khanlou H, et al. A randomized pilot study of tenofovir/emtricitabine (TDF/FTC) + boosted atazanavir (ATV/r) vs. raltegravir (RAL BID) + ATV/r vs. RAL BID + ATV BID. Presented at: Eleventh International Congress on Drug Therapy in HIV Infection; November 11-15, 2012; Glasgow, UK.

 

A Zolopa, J Gallant, C Cohen, P Sax, E Dejesus, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-naïve HIV-1-infected patients. Presented at: Eleventh International Congress on Drug Therapy in HIV Infection; November 11-15, 2012; Glasgow, UK.

 

Cohen CJ, Wohl D, Arribas J, Henry K, et al. STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naïve adults; November 11-15, 2012; Glasgow, UK.
 

 

Cohen CJ, Davis K, Meyers J. Association of partial adherence (PA) to antiretroviral therapy with hospitalizations and healthcare costs in an HIV population. Presented at: Eleventh International Congress on Drug Therapy in HIV Infection; November 11-15, 2012; Glasgow, UK.

 

Cohen CJ, Davis K, Meyers J. Association between selective adherence to antiretroviral therapy and hospitalization risk in an HIV population. Presented at: Fifty-second Interscience Conference on Antimicrobial Agents and Chemotherapy; September 9-12, 2012; San Francisco, CA.

 

Cohen CJ, Molina J, Jayaweera D, et al. Relationship between combination of baseline viral load and CD4 cell count, and Week 48 or 96 responses to rilpivirine (RPV) or efavirenz (EFV) in treatment-naïve HIV-1-infected adults: pooled analysis from the Phase III ECHO and THRIVE trials. Presented at: The Nineteenth Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA.

 

Sax P, DeJesus E, Mills A, Zolopa A, Cohen CJ, et al. The efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF (“Quad”) compared to efavirenz/emtricitabine/tenofovir DF in treatment naïve HIV-1 infected subjects: Primary results of Study GS-US-236-0102. Presented at: The Nineteenth Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA.

 

Cohen CJColson A, Pierone G, Dejesus E, Kinder F, Elion R, Skiest D, Habel A, Jensen J, Garb J, Schrager H, Back D. The FOTO study: The 48 week extension to assess durability of the strategy of taking efavirenz, tenofovir and emtricitabine Five days On, Two days Off (FOTO) each week in virologically suppressed patients. Presented at: Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 19-22, 2009; Cape Town, South Africa.